ALDEYRA THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $33.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-27
- ALDEYRA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $33.85M, a 39.40% decline from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $55.85M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $33.85M 10-K · filed 2026-02-27 |
| 2024-12-31 | $55.85M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |